Former Big Pharma Consultant ‘Shocked’ by ‘Hazardous’ Vaccine Production
Hedley Rees expressed concern about the potential risks associated with allowing untrained volunteers to decant vaccine vials into individual doses, which could result in ‘hot spots’ of vaccine damage.
An ex-consultant for big pharma’s supply chains was shocked by the rapid development and manufacturing process of the COVID-19 jabs.
Mr. Rees, a reform advocate for the pharmaceutical industry, questioned the speedy vaccine approval process, starting just over nine months after the WHO declared a pandemic in March 2020.
He raised awareness about the lack of attention most people pay to the manufacturing processes behind the drugs prescribed by doctors, comparing it to the strict standards in the aviation industry.
He highlighted the unconventional ‘point of care’ manufacturing process of decanting vials into syringes, emphasizing the temperature sensitivity of biological components which, if stored incorrectly, could compromise the vaccine’s sterility and potency.
Related Stories
He voiced concerns about the risks associated with untrained individuals conducting crucial manufacturing tasks, such as thawing and mixing, stressing the importance of a controlled environment and precise procedures for ensuring proper molecular composition.
Mr. Rees highlighted the unique practice of end-stage manufacturing being carried out by non-industry individuals, mentioning the need for untrained personnel to mix saline diluent salt into vaccine vials before administering them.
He speculated that incorrect mixing by non-experts could explain the observed “hot spots” of adverse reactions in certain batches of vaccines, varying from severe harm to no effects at all.
Emphasizing the potential toxicity of drugs at any manufacturing stage, he discussed the historical implications of supply chain adulteration and the importance of stringent validation processes to prevent harmful substitutions.
He criticized the rushed manufacturing process, pointing out that clinical trials can be accelerated, but building a safe supply chain takes considerably longer.
Mr. Rees also questioned the inspection process by the MHRA after Oxford Biomedics took over vaccine production, expressing astonishment at the quick approval despite the potential risks involved.
Reflecting on his experience in the pharmaceutical industry, he criticized the declining standards, increased outsourcing, and profit-driven focus on blockbuster drugs.
He highlighted the UK’s prominent role in pharmaceuticals and collaboration with Bill Gates to establish a global vaccine supply chain, with the MHRA being at the forefront of vaccine approvals.
